Cellosaurus PEO1 (CVCL_2686)

Cell line name PEO1
Synonyms PE01; PEO-1; PEO
Accession CVCL_2686
Resource Identification Initiative To cite this cell line use: PEO1 (RRID:CVCL_2686)
Comments Part of: MD Anderson Cell Lines Project.
Part of: OCCP ovarian cancer cell line panel.
Doubling time: ~37 hours (ECACC).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease BRCA1 syndrome (NCIt: C36100)
Ovarian cystadenocarcinoma (NCIt: C5228)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_Y032 (PEO1-CDDP)
Originate from same individual CVCL_2690 ! PEO4
CVCL_2691 ! PEO6
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; ECACC; PubMed=25230021; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,12
D13S31710
D16S5399
D18S5116,17
D19S43313,15
D21S1132.2
D2S133820,21
D3S135816
D5S81811,12
D7S82010
D8S117913,14 (PubMed=25230021)
13 (PubMed=25877200)
FGA20
Penta D14
Penta E11,12
TH019.3
TPOX9,11
vWA15,16
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=3167863
Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A., Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Cancer Res. 48:6166-6172(1988)

PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Int. J. Cancer 67:816-820(1996)

PubMed=9041185
Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Cancer Res. 57:850-856(1997)

PubMed=20581869; DOI=10.1038/onc.2010.245
Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J., Langdon S.P., Huntsman D., Brenton J.D.
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Oncogene 29:4905-4913(2010)

PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170
Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Genomic complexity and AKT dependence in serous ovarian cancer.
Cancer Discov. 2:56-67(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=25230021; DOI=10.1371/journal.pone.0103988
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028
Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M.
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Gynecol. Oncol. 142:332-340(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27561551; DOI=10.1038/ncomms12645
Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat. Commun. 7:12645-12645(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ECACC; 10032308
Ximbio; 151672
Cell line databases/resources Cosmic-CLP; 1480372
GDSC; 1480372
Ontologies BTO; BTO:0005796
EFO; EFO_0005445
Biological sample resources BioSample; SAMN03473296
Gene expression databases GEO; GSM185145
GEO; GSM185146
GEO; GSM459703
GEO; GSM459853
GEO; GSM723253
GEO; GSM851938
GEO; GSM1670347
Polymorphism and mutation databases Cosmic; 991317
Cosmic; 1102826
Cosmic; 1305316
Cosmic; 1524353
Cosmic; 1709263